1-4 of 4
Alex Legg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial

Priyanka Mehta, Roderick Murphy, Saemi Park, Nalina Dronamraju, Tony Wagner, Yana Lutska, Stefan Faderl, Ian Thomas, Joanna Canham, Alex Legg
Journal: Blood
Blood (2024) 144 (Supplement 1): 55.
https://doi.org/10.1182/blood-2024-207094
Published: 2024
Journal Articles

CREST-UK: CPX-351 Real-World Effectiveness and Safety Study for the Treatment of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes in the UK

Priyanka Mehta, Anjum Khan, Jamie Maddox, Yngvar Floisand, Richard Whitmill, Daniel Cuadras, Montse Pedros, Saemi Park, Greg Medalla, Alex Legg, Victoria Louise Campbell
Journal: Blood
Blood (2022) 140 (Supplement 1): 6152–6154.
https://doi.org/10.1182/blood-2022-159496
Published: 2022
Journal Articles

Real-World Study of CPX-351 Treatment Outcomes for Acute Myeloid Leukemia (AML) in England

Alex Legg, Pesheya Doubleday, Adam Reich, Alexandrina Lambova, Greg Medalla
Journal: Blood
Blood (2021) 138 (Supplement 1): 2310.
https://doi.org/10.1182/blood-2021-148450
Published: 2021
Journal Articles

Real-World Study of the Treatment Patterns of Patients Diagnosed with Therapy-Related AML or AML-MRC in England between 2013 and 2020 Using the Cancer Analysis System Database

Alex Legg, Ruvimbo Muzwidzwa, Elizabeth Adamson, Emily Wilkes, Greg Medalla
Journal: Blood
Blood (2021) 138 (Supplement 1): 1248.
https://doi.org/10.1182/blood-2021-148159
Published: 2021